Dennis Sullivan
Concepts (350)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Veterans | 12 | 2023 | 619 | 3.250 |
Why?
| Tai Ji | 3 | 2022 | 38 | 2.250 |
Why?
| Energy Intake | 8 | 2016 | 196 | 2.000 |
Why?
| Apathy | 5 | 2020 | 47 | 1.980 |
Why?
| Nutrition Assessment | 8 | 2016 | 80 | 1.940 |
Why?
| Muscle, Skeletal | 13 | 2018 | 847 | 1.510 |
Why?
| Walking | 5 | 2023 | 110 | 1.510 |
Why?
| Aged | 60 | 2018 | 10061 | 1.450 |
Why?
| Exercise Therapy | 5 | 2017 | 123 | 1.400 |
Why?
| Resistance Training | 5 | 2018 | 102 | 1.380 |
Why?
| Patient Discharge | 8 | 2023 | 353 | 1.330 |
Why?
| Hospitalization | 6 | 2016 | 704 | 1.310 |
Why?
| Aged, 80 and over | 32 | 2018 | 3431 | 1.230 |
Why?
| Frail Elderly | 5 | 2007 | 32 | 1.180 |
Why?
| Activities of Daily Living | 8 | 2017 | 204 | 1.130 |
Why?
| Geriatric Assessment | 10 | 2015 | 126 | 1.060 |
Why?
| Alzheimer Disease | 6 | 2018 | 369 | 1.050 |
Why?
| Inflammation | 4 | 2012 | 678 | 1.050 |
Why?
| Mortality | 6 | 2007 | 102 | 1.040 |
Why?
| Rehabilitation Centers | 5 | 2012 | 37 | 1.030 |
Why?
| Nutritional Status | 9 | 2016 | 158 | 0.960 |
Why?
| Muscle Weakness | 4 | 2011 | 46 | 0.950 |
Why?
| Male | 60 | 2020 | 27348 | 0.900 |
Why?
| Humans | 74 | 2023 | 54397 | 0.880 |
Why?
| Aging | 11 | 2018 | 784 | 0.880 |
Why?
| Dietary Supplements | 2 | 2018 | 457 | 0.870 |
Why?
| Serum Albumin | 4 | 2012 | 62 | 0.840 |
Why?
| Insulin-Like Growth Factor I | 4 | 2018 | 137 | 0.790 |
Why?
| Weight Gain | 5 | 2012 | 244 | 0.770 |
Why?
| Weight Loss | 5 | 2012 | 271 | 0.760 |
Why?
| Weight Lifting | 6 | 2007 | 31 | 0.750 |
Why?
| Hip Fractures | 3 | 2009 | 52 | 0.750 |
Why?
| Postural Balance | 2 | 2020 | 61 | 0.750 |
Why?
| Advance Care Planning | 2 | 2017 | 25 | 0.730 |
Why?
| Head | 1 | 2020 | 78 | 0.720 |
Why?
| Accidental Falls | 2 | 2020 | 98 | 0.710 |
Why?
| Protein-Energy Malnutrition | 4 | 2002 | 16 | 0.710 |
Why?
| Prospective Studies | 15 | 2018 | 2606 | 0.690 |
Why?
| Depressive Disorder | 2 | 2020 | 368 | 0.690 |
Why?
| Middle Aged | 29 | 2020 | 13083 | 0.690 |
Why?
| Inpatients | 4 | 2016 | 206 | 0.680 |
Why?
| Hospitals, Veterans | 6 | 2015 | 125 | 0.660 |
Why?
| Thigh | 1 | 2018 | 40 | 0.660 |
Why?
| Muscle Strength | 3 | 2011 | 132 | 0.660 |
Why?
| Female | 44 | 2020 | 28474 | 0.650 |
Why?
| Teaching | 1 | 2019 | 125 | 0.650 |
Why?
| Vascular Endothelial Growth Factor D | 1 | 2018 | 8 | 0.640 |
Why?
| User-Computer Interface | 1 | 2018 | 93 | 0.640 |
Why?
| Blood Urea Nitrogen | 1 | 2018 | 51 | 0.630 |
Why?
| Advance Directives | 2 | 2017 | 36 | 0.630 |
Why?
| Medication Therapy Management | 1 | 2018 | 24 | 0.620 |
Why?
| Image Interpretation, Computer-Assisted | 1 | 2018 | 119 | 0.620 |
Why?
| Nursing Homes | 3 | 2011 | 126 | 0.600 |
Why?
| Megestrol Acetate | 6 | 2007 | 17 | 0.600 |
Why?
| Sensation Disorders | 1 | 2017 | 14 | 0.590 |
Why?
| Transcranial Magnetic Stimulation | 1 | 2018 | 81 | 0.580 |
Why?
| Enteral Nutrition | 3 | 2004 | 136 | 0.570 |
Why?
| Fear | 1 | 2017 | 87 | 0.560 |
Why?
| Body Weight | 6 | 2012 | 578 | 0.550 |
Why?
| Physician-Patient Relations | 1 | 2017 | 134 | 0.550 |
Why?
| Kidney Failure, Chronic | 1 | 2018 | 232 | 0.530 |
Why?
| Exercise | 10 | 2009 | 552 | 0.530 |
Why?
| Malnutrition | 2 | 2013 | 82 | 0.510 |
Why?
| Immune System | 1 | 2015 | 49 | 0.510 |
Why?
| RNA, Messenger | 3 | 2018 | 1203 | 0.510 |
Why?
| Videoconferencing | 1 | 2015 | 40 | 0.500 |
Why?
| Adaptation, Physiological | 1 | 2015 | 103 | 0.500 |
Why?
| C-Reactive Protein | 3 | 2012 | 159 | 0.500 |
Why?
| Clinical Protocols | 1 | 2015 | 122 | 0.490 |
Why?
| Tomography, X-Ray Computed | 3 | 2018 | 1222 | 0.470 |
Why?
| Edema | 2 | 2012 | 74 | 0.460 |
Why?
| Neuropsychological Tests | 1 | 2015 | 363 | 0.450 |
Why?
| Hospital Units | 1 | 2012 | 13 | 0.450 |
Why?
| Prealbumin | 2 | 2012 | 24 | 0.440 |
Why?
| Physical Endurance | 1 | 2012 | 49 | 0.440 |
Why?
| Recovery of Function | 2 | 2012 | 222 | 0.430 |
Why?
| Leg | 1 | 2012 | 130 | 0.430 |
Why?
| Treatment Outcome | 11 | 2018 | 5612 | 0.410 |
Why?
| Heart Failure | 1 | 2018 | 541 | 0.410 |
Why?
| Attitude to Death | 1 | 2011 | 11 | 0.400 |
Why?
| Terminally Ill | 1 | 2011 | 15 | 0.400 |
Why?
| Assisted Living Facilities | 1 | 2011 | 16 | 0.400 |
Why?
| Family Relations | 1 | 2011 | 25 | 0.400 |
Why?
| Testosterone | 5 | 2005 | 119 | 0.390 |
Why?
| Professional-Family Relations | 1 | 2011 | 47 | 0.390 |
Why?
| Antidepressive Agents | 1 | 2012 | 187 | 0.380 |
Why?
| Dietary Proteins | 1 | 2012 | 230 | 0.360 |
Why?
| Sound | 1 | 2009 | 11 | 0.360 |
Why?
| Palliative Care | 1 | 2011 | 188 | 0.340 |
Why?
| Muscular Diseases | 1 | 2009 | 65 | 0.330 |
Why?
| Pilot Projects | 5 | 2018 | 807 | 0.330 |
Why?
| Nutrition Disorders | 2 | 1998 | 11 | 0.320 |
Why?
| Geriatrics | 1 | 2008 | 47 | 0.310 |
Why?
| Proportional Hazards Models | 4 | 2018 | 430 | 0.300 |
Why?
| Prognosis | 5 | 2018 | 2126 | 0.300 |
Why?
| Food Service, Hospital | 2 | 2016 | 4 | 0.290 |
Why?
| Double-Blind Method | 5 | 2018 | 743 | 0.290 |
Why?
| Disabled Persons | 1 | 2008 | 105 | 0.290 |
Why?
| Photography | 2 | 2016 | 39 | 0.290 |
Why?
| Syndrome | 2 | 2020 | 253 | 0.280 |
Why?
| Hypoalbuminemia | 1 | 2005 | 5 | 0.270 |
Why?
| Diet | 3 | 2016 | 598 | 0.260 |
Why?
| Skin Ulcer | 2 | 2015 | 12 | 0.260 |
Why?
| Body Mass Index | 8 | 2009 | 712 | 0.250 |
Why?
| Interleukin-6 | 4 | 2012 | 315 | 0.250 |
Why?
| Cognition | 3 | 2018 | 350 | 0.250 |
Why?
| Body Composition | 7 | 2009 | 349 | 0.250 |
Why?
| Methylphenidate | 2 | 2017 | 94 | 0.240 |
Why?
| Feasibility Studies | 3 | 2015 | 398 | 0.240 |
Why?
| Postoperative Care | 1 | 2004 | 121 | 0.240 |
Why?
| Cytokines | 1 | 2007 | 677 | 0.240 |
Why?
| Cohort Studies | 4 | 2012 | 1547 | 0.240 |
Why?
| Time Factors | 7 | 2017 | 3210 | 0.230 |
Why?
| Obesity | 5 | 2009 | 1203 | 0.230 |
Why?
| Health Status | 3 | 2018 | 368 | 0.230 |
Why?
| Tumor Necrosis Factor-alpha | 3 | 2012 | 435 | 0.230 |
Why?
| Appetite | 2 | 2003 | 19 | 0.220 |
Why?
| Diet Records | 2 | 2016 | 24 | 0.220 |
Why?
| Aftercare | 1 | 2023 | 82 | 0.220 |
Why?
| Adipose Tissue | 2 | 2018 | 208 | 0.210 |
Why?
| Central Nervous System Stimulants | 2 | 2017 | 255 | 0.210 |
Why?
| Homes for the Aged | 1 | 2002 | 33 | 0.210 |
Why?
| Risk Factors | 5 | 2016 | 3937 | 0.200 |
Why?
| Cyclobutanes | 1 | 2001 | 3 | 0.200 |
Why?
| Appetite Depressants | 1 | 2001 | 10 | 0.200 |
Why?
| Cross-Over Studies | 2 | 2018 | 250 | 0.200 |
Why?
| Muscle Proteins | 4 | 2009 | 307 | 0.200 |
Why?
| Intubation, Gastrointestinal | 1 | 2000 | 27 | 0.190 |
Why?
| Magnetics | 1 | 2000 | 44 | 0.190 |
Why?
| Independent Living | 2 | 2017 | 46 | 0.180 |
Why?
| Energy Metabolism | 2 | 2009 | 311 | 0.180 |
Why?
| Adult | 11 | 2019 | 14210 | 0.180 |
Why?
| Outpatients | 1 | 2020 | 122 | 0.180 |
Why?
| Quality Improvement | 1 | 2022 | 245 | 0.170 |
Why?
| Algorithms | 1 | 2023 | 697 | 0.170 |
Why?
| Arkansas | 5 | 2008 | 2101 | 0.170 |
Why?
| Hospital Mortality | 2 | 2018 | 466 | 0.170 |
Why?
| Muscles | 2 | 2016 | 114 | 0.160 |
Why?
| Follow-Up Studies | 2 | 2017 | 2390 | 0.160 |
Why?
| Coronary Artery Disease | 1 | 2002 | 329 | 0.160 |
Why?
| Organ Size | 1 | 2018 | 237 | 0.160 |
Why?
| Human Growth Hormone | 1 | 1998 | 51 | 0.160 |
Why?
| Mental Status Schedule | 1 | 2017 | 19 | 0.150 |
Why?
| Executive Function | 1 | 2018 | 80 | 0.150 |
Why?
| United States | 4 | 2015 | 5209 | 0.150 |
Why?
| Age Factors | 4 | 2015 | 1199 | 0.140 |
Why?
| Nutritional Support | 4 | 2013 | 35 | 0.140 |
Why?
| Video Recording | 1 | 2017 | 90 | 0.140 |
Why?
| Reproducibility of Results | 2 | 2016 | 1301 | 0.140 |
Why?
| Wound Healing | 2 | 2015 | 228 | 0.140 |
Why?
| Pandemics | 1 | 2022 | 594 | 0.140 |
Why?
| Cross-Sectional Studies | 2 | 2020 | 1697 | 0.140 |
Why?
| Hyperinsulinism | 2 | 2006 | 27 | 0.140 |
Why?
| Meals | 1 | 2016 | 62 | 0.140 |
Why?
| Caenorhabditis elegans | 1 | 2016 | 147 | 0.140 |
Why?
| Negative-Pressure Wound Therapy | 1 | 2015 | 10 | 0.130 |
Why?
| Health Behavior | 1 | 2017 | 275 | 0.130 |
Why?
| Electric Stimulation Therapy | 1 | 2015 | 26 | 0.130 |
Why?
| Health Status Indicators | 2 | 2008 | 94 | 0.130 |
Why?
| Outpatient Clinics, Hospital | 1 | 2015 | 44 | 0.130 |
Why?
| Retrospective Studies | 4 | 2020 | 6460 | 0.130 |
Why?
| Length of Stay | 2 | 2008 | 683 | 0.130 |
Why?
| Dietary Carbohydrates | 2 | 2006 | 90 | 0.130 |
Why?
| Bone and Bones | 1 | 2018 | 516 | 0.120 |
Why?
| Electronic Health Records | 1 | 2016 | 203 | 0.120 |
Why?
| Tissue Engineering | 1 | 2015 | 61 | 0.120 |
Why?
| Decision Making | 1 | 2016 | 286 | 0.120 |
Why?
| Anti-Infective Agents | 1 | 2015 | 111 | 0.120 |
Why?
| Nutrition Therapy | 1 | 2013 | 22 | 0.120 |
Why?
| Intermediate Care Facilities | 1 | 2012 | 6 | 0.110 |
Why?
| Gene Expression Regulation | 2 | 2009 | 1063 | 0.110 |
Why?
| Ubiquitin Thiolesterase | 1 | 2013 | 23 | 0.110 |
Why?
| Ubiquitin | 1 | 2013 | 51 | 0.110 |
Why?
| Regional Blood Flow | 1 | 2012 | 121 | 0.110 |
Why?
| Proteolysis | 1 | 2013 | 102 | 0.110 |
Why?
| Registries | 2 | 2008 | 554 | 0.110 |
Why?
| Citalopram | 1 | 2012 | 19 | 0.110 |
Why?
| Fluoxetine | 1 | 2012 | 47 | 0.110 |
Why?
| Proteasome Endopeptidase Complex | 1 | 2013 | 131 | 0.100 |
Why?
| Patient Care Team | 1 | 2013 | 273 | 0.100 |
Why?
| Narration | 1 | 2011 | 31 | 0.100 |
Why?
| Exercise Tolerance | 1 | 2011 | 48 | 0.100 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2012 | 150 | 0.100 |
Why?
| Oxygen Consumption | 4 | 2009 | 223 | 0.100 |
Why?
| Safety | 2 | 2001 | 92 | 0.090 |
Why?
| Cognition Disorders | 1 | 2012 | 240 | 0.090 |
Why?
| Myofibrils | 2 | 2007 | 21 | 0.090 |
Why?
| T-Lymphocytes | 1 | 2013 | 374 | 0.090 |
Why?
| Mass Screening | 1 | 2013 | 370 | 0.090 |
Why?
| Rural Population | 1 | 2015 | 598 | 0.090 |
Why?
| Abdominal Fat | 1 | 2009 | 11 | 0.090 |
Why?
| Insurance Claim Review | 1 | 2009 | 28 | 0.090 |
Why?
| Sleep | 1 | 2011 | 188 | 0.090 |
Why?
| Polysomnography | 1 | 2009 | 71 | 0.090 |
Why?
| Muscle Development | 1 | 2009 | 25 | 0.090 |
Why?
| Survival Analysis | 2 | 2003 | 736 | 0.090 |
Why?
| Communication | 1 | 2011 | 265 | 0.090 |
Why?
| Adiponectin | 1 | 2009 | 76 | 0.080 |
Why?
| Glucose | 2 | 2007 | 366 | 0.080 |
Why?
| Medicare | 1 | 2009 | 245 | 0.080 |
Why?
| Weightlessness | 1 | 2007 | 14 | 0.080 |
Why?
| Disability Evaluation | 1 | 2008 | 103 | 0.080 |
Why?
| Rest | 1 | 2007 | 68 | 0.080 |
Why?
| Intercellular Signaling Peptides and Proteins | 1 | 2007 | 122 | 0.080 |
Why?
| Predictive Value of Tests | 2 | 2007 | 1045 | 0.070 |
Why?
| Electroencephalography | 1 | 2009 | 357 | 0.070 |
Why?
| Space Flight | 1 | 2007 | 37 | 0.070 |
Why?
| Physical Education and Training | 2 | 2003 | 27 | 0.070 |
Why?
| Severity of Illness Index | 2 | 2017 | 1082 | 0.070 |
Why?
| Glucose Clamp Technique | 1 | 2006 | 19 | 0.070 |
Why?
| Glucose Intolerance | 1 | 2006 | 28 | 0.070 |
Why?
| Glycogen | 1 | 2006 | 45 | 0.070 |
Why?
| Pituitary Hormones, Anterior | 1 | 2005 | 3 | 0.070 |
Why?
| Proteins | 1 | 2009 | 376 | 0.070 |
Why?
| Hormones | 1 | 2005 | 59 | 0.070 |
Why?
| Pituitary Gland | 1 | 2005 | 78 | 0.060 |
Why?
| APACHE | 1 | 2004 | 24 | 0.060 |
Why?
| Interleukin-15 | 1 | 2004 | 19 | 0.060 |
Why?
| Interleukin-18 | 1 | 2004 | 27 | 0.060 |
Why?
| Postoperative Complications | 2 | 2004 | 1035 | 0.060 |
Why?
| Diet, Fat-Restricted | 1 | 2004 | 11 | 0.060 |
Why?
| Regression Analysis | 1 | 2005 | 445 | 0.060 |
Why?
| Marital Status | 1 | 2003 | 20 | 0.060 |
Why?
| Insulin Resistance | 1 | 2006 | 300 | 0.060 |
Why?
| Insulin | 1 | 2006 | 511 | 0.060 |
Why?
| Demography | 1 | 2003 | 103 | 0.060 |
Why?
| Macrophages | 1 | 2006 | 404 | 0.060 |
Why?
| Chi-Square Distribution | 1 | 2003 | 318 | 0.050 |
Why?
| Amino Acids | 1 | 2004 | 369 | 0.050 |
Why?
| Lipids | 1 | 2003 | 178 | 0.050 |
Why?
| Models, Biological | 1 | 2006 | 825 | 0.050 |
Why?
| Chronic Disease | 2 | 2015 | 614 | 0.050 |
Why?
| Gonadal Steroid Hormones | 1 | 2002 | 42 | 0.050 |
Why?
| Analysis of Variance | 3 | 2012 | 634 | 0.050 |
Why?
| Leptin | 1 | 2003 | 154 | 0.050 |
Why?
| Premenopause | 1 | 2001 | 26 | 0.050 |
Why?
| Basal Metabolism | 1 | 2001 | 36 | 0.050 |
Why?
| Enzyme-Linked Immunosorbent Assay | 3 | 2009 | 314 | 0.050 |
Why?
| Drug Therapy, Combination | 2 | 2002 | 426 | 0.050 |
Why?
| Risk | 1 | 2002 | 343 | 0.050 |
Why?
| Socioeconomic Factors | 1 | 2003 | 639 | 0.050 |
Why?
| Radiography, Abdominal | 1 | 2000 | 29 | 0.050 |
Why?
| Gait | 1 | 2001 | 98 | 0.050 |
Why?
| Acute Disease | 1 | 2001 | 403 | 0.050 |
Why?
| Logistic Models | 1 | 2002 | 991 | 0.040 |
Why?
| Heart Rate | 1 | 2001 | 358 | 0.040 |
Why?
| Ciliary Neurotrophic Factor | 2 | 2009 | 11 | 0.040 |
Why?
| Statistics, Nonparametric | 1 | 1999 | 232 | 0.040 |
Why?
| Tissue Inhibitor of Metalloproteinase-1 | 2 | 2009 | 32 | 0.040 |
Why?
| Hypotension, Orthostatic | 1 | 1998 | 4 | 0.040 |
Why?
| Gynecomastia | 1 | 1998 | 5 | 0.040 |
Why?
| Insulin-Like Growth Factor Binding Protein 1 | 1 | 1998 | 8 | 0.040 |
Why?
| Matrix Metalloproteinase 2 | 2 | 2009 | 64 | 0.040 |
Why?
| Insulin-Like Growth Factor Binding Protein 2 | 1 | 1998 | 11 | 0.040 |
Why?
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 1998 | 27 | 0.040 |
Why?
| Cholesterol | 2 | 2012 | 155 | 0.040 |
Why?
| Food, Formulated | 1 | 1997 | 44 | 0.040 |
Why?
| Multivariate Analysis | 1 | 1999 | 643 | 0.040 |
Why?
| Nutritional Requirements | 1 | 1997 | 69 | 0.040 |
Why?
| Hypertension | 1 | 2002 | 565 | 0.040 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 2 | 2009 | 674 | 0.040 |
Why?
| Gene Knockdown Techniques | 1 | 2016 | 125 | 0.040 |
Why?
| Transferrin | 1 | 1996 | 14 | 0.040 |
Why?
| Recombinant Proteins | 1 | 1998 | 570 | 0.040 |
Why?
| RNA Interference | 1 | 2016 | 195 | 0.040 |
Why?
| Multiple Myeloma | 1 | 2011 | 3050 | 0.030 |
Why?
| Arthroplasty | 1 | 1996 | 30 | 0.030 |
Why?
| Quality Indicators, Health Care | 1 | 2016 | 98 | 0.030 |
Why?
| Self Report | 1 | 2016 | 205 | 0.030 |
Why?
| Body Constitution | 2 | 2006 | 12 | 0.030 |
Why?
| Administration, Topical | 1 | 2015 | 71 | 0.030 |
Why?
| Morbidity | 1 | 1995 | 149 | 0.030 |
Why?
| Caregivers | 1 | 2017 | 241 | 0.030 |
Why?
| Canada | 1 | 2015 | 104 | 0.030 |
Why?
| Stress, Physiological | 1 | 1996 | 194 | 0.030 |
Why?
| Triglycerides | 2 | 2007 | 195 | 0.030 |
Why?
| Forecasting | 1 | 2015 | 161 | 0.030 |
Why?
| Injections, Intramuscular | 2 | 2003 | 50 | 0.030 |
Why?
| Cysteine Proteinase Inhibitors | 1 | 2013 | 28 | 0.030 |
Why?
| I-kappa B Proteins | 1 | 2013 | 26 | 0.030 |
Why?
| Comorbidity | 1 | 2015 | 664 | 0.030 |
Why?
| Consensus | 1 | 2013 | 157 | 0.030 |
Why?
| Hemostasis | 1 | 2013 | 55 | 0.030 |
Why?
| Acetylcysteine | 1 | 2013 | 118 | 0.030 |
Why?
| Depression | 1 | 2017 | 596 | 0.030 |
Why?
| Drug Administration Schedule | 2 | 2003 | 401 | 0.030 |
Why?
| Disease Progression | 1 | 2015 | 917 | 0.030 |
Why?
| Biomedical Research | 1 | 2015 | 241 | 0.030 |
Why?
| Muscular Atrophy | 1 | 2011 | 73 | 0.020 |
Why?
| Risk Assessment | 1 | 1995 | 1362 | 0.020 |
Why?
| Animals | 2 | 2016 | 14411 | 0.020 |
Why?
| Spectrometry, X-Ray Emission | 1 | 2009 | 9 | 0.020 |
Why?
| Intra-Abdominal Fat | 1 | 2009 | 22 | 0.020 |
Why?
| Blood Glucose | 1 | 2012 | 489 | 0.020 |
Why?
| Nitrogen | 1 | 2009 | 78 | 0.020 |
Why?
| Leucine | 1 | 2009 | 113 | 0.020 |
Why?
| Quality of Life | 1 | 2015 | 924 | 0.020 |
Why?
| Diabetes Mellitus | 1 | 2012 | 309 | 0.020 |
Why?
| Myostatin | 1 | 2007 | 10 | 0.020 |
Why?
| Insulin-Like Growth Factor Binding Protein 5 | 1 | 2007 | 19 | 0.020 |
Why?
| Actins | 1 | 2007 | 132 | 0.020 |
Why?
| Transforming Growth Factor beta | 1 | 2007 | 158 | 0.020 |
Why?
| Young Adult | 1 | 2016 | 4319 | 0.020 |
Why?
| Muscle Contraction | 1 | 2007 | 111 | 0.020 |
Why?
| Receptor, Macrophage Colony-Stimulating Factor | 1 | 2006 | 5 | 0.020 |
Why?
| Chemokines, CC | 1 | 2006 | 9 | 0.020 |
Why?
| Receptors, Interleukin-1 | 1 | 2006 | 20 | 0.020 |
Why?
| Macrophage Activation | 1 | 2006 | 29 | 0.020 |
Why?
| Antigens, Differentiation, Myelomonocytic | 1 | 2006 | 46 | 0.020 |
Why?
| Progesterone Congeners | 1 | 2005 | 5 | 0.020 |
Why?
| Body Fat Distribution | 1 | 2005 | 11 | 0.020 |
Why?
| Freezing | 1 | 2005 | 15 | 0.020 |
Why?
| Interleukin-1 | 1 | 2006 | 107 | 0.020 |
Why?
| Cell Count | 1 | 2006 | 181 | 0.020 |
Why?
| Serum | 1 | 2005 | 39 | 0.020 |
Why?
| Interleukin-10 | 1 | 2006 | 106 | 0.020 |
Why?
| Interleukin-1beta | 1 | 2006 | 92 | 0.020 |
Why?
| Receptors, Cell Surface | 1 | 2006 | 130 | 0.020 |
Why?
| Parenteral Nutrition Solutions | 1 | 2004 | 8 | 0.020 |
Why?
| Sarcoplasmic Reticulum | 1 | 2004 | 22 | 0.020 |
Why?
| Solutions | 1 | 2004 | 29 | 0.020 |
Why?
| Myosin Heavy Chains | 1 | 2004 | 19 | 0.020 |
Why?
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2004 | 19 | 0.020 |
Why?
| Electrolytes | 1 | 2004 | 25 | 0.020 |
Why?
| Deuterium | 1 | 2004 | 41 | 0.020 |
Why?
| Antigens, CD | 1 | 2006 | 242 | 0.020 |
Why?
| Protein Isoforms | 1 | 2004 | 124 | 0.020 |
Why?
| Infusions, Intravenous | 1 | 2004 | 231 | 0.020 |
Why?
| Phenylalanine | 1 | 2004 | 125 | 0.020 |
Why?
| Phosphoproteins | 1 | 2004 | 116 | 0.020 |
Why?
| Mice | 1 | 2015 | 6429 | 0.010 |
Why?
| Muscle Fibers, Skeletal | 1 | 2004 | 78 | 0.010 |
Why?
| Adaptor Proteins, Signal Transducing | 1 | 2004 | 208 | 0.010 |
Why?
| Cholesterol, HDL | 1 | 2003 | 42 | 0.010 |
Why?
| Hormone Replacement Therapy | 1 | 2003 | 27 | 0.010 |
Why?
| Cell Cycle Proteins | 1 | 2004 | 198 | 0.010 |
Why?
| Phosphorylation | 1 | 2004 | 613 | 0.010 |
Why?
| Amino Acids, Essential | 1 | 2004 | 133 | 0.010 |
Why?
| Immunohistochemistry | 1 | 2006 | 1090 | 0.010 |
Why?
| Probability | 1 | 2003 | 177 | 0.010 |
Why?
| Carrier Proteins | 1 | 2004 | 360 | 0.010 |
Why?
| Protein Biosynthesis | 1 | 2004 | 273 | 0.010 |
Why?
| Randomized Controlled Trials as Topic | 1 | 2005 | 594 | 0.010 |
Why?
| Gene Expression Profiling | 1 | 2007 | 1141 | 0.010 |
Why?
| Reference Values | 1 | 2003 | 354 | 0.010 |
Why?
| Biopsy | 1 | 2004 | 692 | 0.010 |
Why?
| Sensitivity and Specificity | 1 | 2003 | 922 | 0.010 |
Why?
| Dose-Response Relationship, Drug | 1 | 2003 | 1477 | 0.010 |
Why?
| Postoperative Period | 1 | 1996 | 189 | 0.010 |
Why?
| Adolescent | 1 | 1996 | 6901 | 0.000 |
Why?
|
|
Sullivan's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|